Prasugrel could be $1b drug
Nov. 20 - Japanese drugmaker Daiichi Sankyo says it's in the last stages of getting approval for its blood clot prevention drug Prasugrel from the U.S. Food & Drug Administration.
US CEO Joe Peroni, speaking at the Reuters Health Summit in New York on Thursday, said Prasugrel could eventually be a $1 billion drug because "this is a very big category and it's a very good product so I do think that we can achieve this level." Speaker: Joe Peroni CEO, Daiichi Sankyo US Presenter: Bobbi Rebell New York
No videos currently selected.
Click 
on any video below, from any channel, to add it to your playlist.
Marilyn Monroe smoking "pot"?
Featured Videos
Reuters.com:
Help and Contact Us |
Advertise With Us |
Mobile |
Newsletters |
RSS
|
Labs |
Journalism Handbook |
Archive |
Site Index |
Video Index
Thomson Reuters Corporate: Copyright | Disclaimer | Privacy | Professional Products | Professional Products Support | About Thomson Reuters | Careers
International Editions: Africa | Arabic | Argentina | Brazil | Canada | China | France | Germany | India | Italy | Japan | Latin America | Mexico | Russia | Spain | United Kingdom | United States
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
